Fig. 3: Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis. | Nature Medicine

Fig. 3: Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis.

From: The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Fig. 3: Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis.

a–c, Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis. Effects of dapagliflozin versus placebo at 12 weeks on 6MWT distance (a), KCCQ-CS responder analysis (b) and KCCQ-OS (c). Data are presented as mean values with 95% CI. a,c, An F-test was used in data analysis; b, a chi-square test was used in data analysis All P values are two-sided, with no adjustments made for multiple comparisons.

Back to article page